Refine
Year of publication
- 2021 (1)
Document Type
- Article (1)
Language
- English (1)
Has Fulltext
- yes (1)
Is part of the Bibliography
- no (1)
Keywords
- Alpha-fetoprotein (AFP) (1)
- Cabozantinib (1)
- Hepatocellular carcinoma (HCC) (1)
- Indirect treatment comparison (ITC) (1)
- Matching-adjusted indirect comparison (MAIC) (1)
- Monoclonal antibody (mAb) (1)
- Ramucirumab (1)
- Tyrosine kinase inhibitor (TKI) (1)
- Vascular endothelial growth factor (VEGF) (1)
- second-line treatment / 2L treatment (1)
Institute
- Medizin (1)
Individual patient data (IPD) from the CELESTIAL trial (cabozantinib) and population-level data from the REACH-2 trial (ramucirumab) were used. To align with REACH-2, the CELESTIAL population was limited to patients who received first-line sorafenib only and had baseline serum AFP ≥ 400 ng/mL. The IPD from CELESTIAL were weighted to balance the distribution of 11 effect-modifying baseline characteristics with those of REACH-2. Overall survival (OS; primary endpoint) and progression-free survival (PFS) were compared for the CELESTIAL (matching-adjusted) and REACH-2 populations using weighted Kaplan-Meier (KM) curves and parametric (OS, Weibull; PFS, log-logistic) modeling. Rates of treatment-related adverse events (TRAEs) and TRAE-related discontinuations were also compared.